## Edgar Filing: LEXICON PHARMACEUTICALS, INC./DE - Form 4

LEXICON I Form 4 February 11	PHARMACEUTI	CALS, II	NC./DE								
•	ЛЛ									PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISS Washington, D.C. 20549							COMMISSIO	N OMB Number:	3235-0287		
if no lon	iger STATEN	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								January 31, 2005	
subject t Section Form 4 (	16.									average Jrs per . 0.5	
Form 5 obligatio may com <i>See</i> Instr 1(b).	ons Section 17(	a) of the l	Public U		ding Cor	npany A	Act of	e Act of 1934, f 1935 or Secti 40		. 0.0	
(Print or Type	Responses)										
PIGGOTT JAMES R PHD Sy				2. Issuer Name <b>and</b> Ticker or Trading Symbol LEXICON PHARMACEUTICALS, INC./DE [LXRX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (	Middle)		E [LXKX	-			Director	104	% Owner	
(Mc				(Month/Dav/Year) —				_X_ Officer (give title Other (specify below) below) SVP of Pharm Bio			
	(Street)			endment, Date Original nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
THE WOODLA	NDS, TX 773811	160						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securitie	es Acq	uired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)			TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A)			5 S B C F R T	A Amount of Securities Beneficially Owned Collowing Reported Cransaction(s) Instr. 3 and 4)		7. Nature of Indirect	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year) 4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code V	(A) (	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 2.07	02/07/2008		A	50,000		<u>(1)</u>	02/07/2018	Common Stock	50,000

## Edgar Filing: LEXICON PHARMACEUTICALS, INC./DE - Form 4

## **Reporting Owners**

Relationships						
Director	10% Owner	Officer	Other			
		SVP of Pharm Bio				
	Director		Director 10% Owner Officer			

/s/ Piggott, 02/08/2008 James R.

<u>\*\*</u>Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/7/2009) and vests 1/48th per month for each month of service thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.